The drug maker was granted the license for the process for preparing dolastatin 10 derivative and anti-cancer agents comprising the same.
“Dolastatin 10 derivative which constitutes CT-P26 is proven to outsmart existing carcinostatis substances in terms of anti-cancer activity for breast, colorectal, lung and stomach cancer,” Celltrion said in a regulatory filing.
CT-P26 has obtained patents in several countries including Korea, the US and European nations. The pharmaceutical firm is waiting for a license in Japan, China and Canada.
The derivative of dolastatin 10 is already applied to a biobetter of Celltrion’s Herzuma, a biosimilar of Roche’s blockbuster breast cancer treatment Herceptin, the company said.
Celltrion plans to submit Herzuma to the European Medicines Agency this quarter for review.
By Park Han-na (firstname.lastname@example.org)